Skip to content 
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York. more
| Time Frame | DRUG | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 3.05% | 0.91% | -0.82% |
| 1-Month Return | -3.25% | 1.46% | 1.28% |
| 3-Month Return | 39.1% | 3.33% | 3.98% |
| 6-Month Return | 76.29% | 16.03% | 6.73% |
| 1-Year Return | 114.08% | 9.1% | 12.24% |
| 3-Year Return | 2146.15% | 21.02% | 72.07% |
| 5-Year Return | 197.41% | 36.15% | 75.69% |
| Sep '21 | Sep '22 | Sep '23 | Sep '24 | Sep '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Cost of Revenue | - | 6.04K | 72.45K | - | 55.19K | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":8.33,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":76.18,"profit":true}] |
| Gross Profit | - | (6.04K) | (72.45K) | - | (55.19K) | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":-603700,"profit":false},{"date":"2023-09-30","value":-7245000,"profit":false},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":-5519100,"profit":false}] |
| Gross Margin | - | - | - | - | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Operating Expenses | 8.60M | 14.73M | 7.20M | 2.62M | 9.93M | [{"date":"2021-09-30","value":58.41,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":48.87,"profit":true},{"date":"2024-09-30","value":17.76,"profit":true},{"date":"2025-09-30","value":67.38,"profit":true}] |
| Operating Income | (8.76M) | (14.73M) | (7.20M) | (2.62M) | (13.94M) | [{"date":"2021-09-30","value":-875855300,"profit":false},{"date":"2022-09-30","value":-1473201200,"profit":false},{"date":"2023-09-30","value":-719976300,"profit":false},{"date":"2024-09-30","value":-261663600,"profit":false},{"date":"2025-09-30","value":-1393758400,"profit":false}] |
| Total Non-Operating Income/Expense | 89.13K | (232.93K) | (172.46K) | (155.18K) | 3.23M | [{"date":"2021-09-30","value":2.76,"profit":true},{"date":"2022-09-30","value":-7.22,"profit":false},{"date":"2023-09-30","value":-5.34,"profit":false},{"date":"2024-09-30","value":-4.81,"profit":false},{"date":"2025-09-30","value":100,"profit":true}] |
| Pre-Tax Income | (8.65M) | (14.96M) | (7.37M) | (2.80M) | (12.23M) | [{"date":"2021-09-30","value":-865076300,"profit":false},{"date":"2022-09-30","value":-1496494000,"profit":false},{"date":"2023-09-30","value":-737222500,"profit":false},{"date":"2024-09-30","value":-280194600,"profit":false},{"date":"2025-09-30","value":-1222934800,"profit":false}] |
| Income Taxes | (135.43K) | 222.78K | (14.19K) | - | - | [{"date":"2021-09-30","value":-60.79,"profit":false},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":-6.37,"profit":false},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Income After Taxes | (8.52M) | (15.19M) | (7.36M) | - | - | [{"date":"2021-09-30","value":-851532900,"profit":false},{"date":"2022-09-30","value":-1518771700,"profit":false},{"date":"2023-09-30","value":-735803600,"profit":false},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Income From Continuous Operations | (8.65M) | (14.96M) | (7.37M) | (2.80M) | (12.23M) | [{"date":"2021-09-30","value":-865076300,"profit":false},{"date":"2022-09-30","value":-1496494100,"profit":false},{"date":"2023-09-30","value":-737222500,"profit":false},{"date":"2024-09-30","value":-280194600,"profit":false},{"date":"2025-09-30","value":-1222934800,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true},{"date":"2025-09-30","value":"-","profit":true}] |
| Net Income | (8.52M) | (14.96M) | (7.37M) | (2.80M) | (12.23M) | [{"date":"2021-09-30","value":-851532900,"profit":false},{"date":"2022-09-30","value":-1496494000,"profit":false},{"date":"2023-09-30","value":-737222500,"profit":false},{"date":"2024-09-30","value":-280194600,"profit":false},{"date":"2025-09-30","value":-1222934800,"profit":false}] |
| EPS (Diluted) | (0.61) | (0.94) | (0.77) | (0.55) | (1.73) | [{"date":"2021-09-30","value":-61.05,"profit":false},{"date":"2022-09-30","value":-94.37,"profit":false},{"date":"2023-09-30","value":-76.59,"profit":false},{"date":"2024-09-30","value":-55.11,"profit":false},{"date":"2025-09-30","value":-173,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| DRUG | |
|---|---|
| Current Ratio | 57.37 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| DRUG | |
|---|---|
| ROA (LTM) | -15.72% |
| ROE (LTM) | -26.98% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| DRUG | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.02 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.98 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| DRUG | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 12.49 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Bright Minds Biosciences Inc (DRUG) share price today is $81.501
Yes, Indians can buy shares of Bright Minds Biosciences Inc (DRUG) on Vested. To buy
Yes, you can purchase fractional shares of Bright Minds Biosciences Inc (DRUG) via the Vested app. You can start investing in Bright Minds Biosciences Inc (DRUG) with a minimum investment of $1.
You can invest in shares of Bright Minds Biosciences Inc (DRUG) via Vested in three simple steps:
The 52-week high price of Bright Minds Biosciences Inc (DRUG) is $123.75. The 52-week low price of Bright Minds Biosciences Inc (DRUG) is $23.18.
The price-to-earnings (P/E) ratio of Bright Minds Biosciences Inc (DRUG) is
The price-to-book (P/B) ratio of Bright Minds Biosciences Inc (DRUG) is 12.49
The dividend yield of Bright Minds Biosciences Inc (DRUG) is 0.00%
The market capitalization of Bright Minds Biosciences Inc (DRUG) is $781.49M
The stock symbol (or ticker) of Bright Minds Biosciences Inc is DRUG
Consider the share price of Bright Minds Biosciences Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Bright Minds Biosciences Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Bright Minds Biosciences Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Bright Minds Biosciences Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Bright Minds Biosciences Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Bright Minds Biosciences Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
